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BACKGROUND: Bevacizumab plus interferon-a2a (IFN) prolongs progression-free survival to 410 months, which is comparable with
sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have different tolerability profiles;
therefore, costs for managing adverse events may be an important factor in selecting therapy.
METHODS: Costs of managing adverse events affecting patients with metastatic RCC eligible for treatment with bevacizumab plus IFN
or sunitinib were evaluated using a linear decision analytical model. Management costs were calculated from the published incidence
of adverse events and health-care costs for treating adverse events in the United Kingdom, Germany, France and Italy.
RESULTS: Adverse event management costs were higher for sunitinib than for bevacizumab plus IFN. The average cost per patient for
the management of grade 3–4 adverse events was markedly lower with bevacizumab plus IFN compared with sunitinib in the United
Kingdom (h1475 vs h804), Germany (h1785 vs h1367), France (h2590 vs h1618) and Italy (h891 vs h402). The main cost drivers
were lymphopaenia, neutropaenia, thrombocytopaenia, leucopaenia and fatigue/asthaenia for sunitinib; and proteinuria, fatigue/
asthaenia, bleeding, anaemia and gastrointestinal perforation for bevacizumab plus IFN.
CONCLUSION: The costs of managing adverse events are lower for bevacizumab plus IFN than for sunitinib. The potential for cost
savings should be considered when selecting treatments for RCC.
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Renal cell carcinoma (RCC) is the most common cancer of the
kidney, with an incidence of 40 000 (3.1% of all cancer cases)
annually and accounting for 26 000 deaths (2.3% of all cancer
deaths) in Europe (Ferlay et al, 2007). The treatment landscape for
metastatic RCC is changing, as a greater understanding of the
biological processes involved in RCC development and growth, in
particular the function of tumour angiogenesis, supports the
development of more specific and effective therapies.
Bevacizumab (Avastin) is a humanised monoclonal antibody
that precisely inhibits vascular endothelial growth factor (VEGF),
the key mediator of tumour angiogenesis. In combination with
cytotoxic chemotherapy, bevacizumab has demonstrated signifi-
cant clinical benefits in several tumour types including metastatic
colorectal (Hurwitz et al, 2004; Saltz et al, 2008), breast (Miller
et al, 2007; Miles et al, 2008) and non-small-cell lung cancer
(Sandler et al, 2006; Manegold et al, 2007). In metastatic RCC,
initial phase II trials demonstrated that bevacizumab monotherapy
is active and well tolerated in previously treated and treatment-
naive patients (Yang et al, 2003; Bukowski et al, 2007). A large
international, double-blind, randomised, controlled phase III trial
(AVOREN) demonstrated that first-line bevacizumab combined
with interferon-a2a (IFN, Roferon) significantly improved median
progression-free survival (PFS: 10.2 vs 5.4 months; hazard ratio
(HR)¼ 0.63, P¼ 0.0001) and objective response rate (ORR: 31 vs
13%, P¼ 0.0001) compared with IFN plus placebo (Escudier et al,
2007). On the basis of these positive data, bevacizumab combined
with IFN is approved in Europe for the first-line treatment of
patients with advanced and/or metastatic RCC. A second phase III
study, conducted in the United States (CALGB 90206), confirmed
the significant benefit of bevacizumab and IFN vs IFN, with
improvements in median PFS (8.5 vs 5.2 months; HR¼ 0.71,
Po0.001) and ORR (26 vs 13%, Po0.001) (Rini et al, 2008).
A number of other novel biological agents are available for the
treatment of metastatic RCC, including sunitinib malate (Sutent),
an orally active inhibitor of multiple receptor tyrosine kinases
including VEGF receptors 1– 3 and platelet-derived growth factor
receptor-a and -b (Mendel et al, 2003). Sunitinib is also approved
for first-line treatment of metastatic RCC on the basis of an
open-label phase III trial showing significant improvement in ORR
(47 vs 12%, Po0.0001) and median PFS (11.0 vs 5.0 months;
HR¼ 0.539, Po0.001) when compared with IFN (Motzer et al,
2007).
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The results of these recent phase III trials in RCC suggest that
the efficacy of bevacizumab plus IFN is comparable with that of
sunitinib in the first-line treatment setting (Escudier et al, 2007;
Motzer et al, 2007; Coppin et al, 2008). However, clinical data
suggest that the two regimens have different tolerability profiles
with respect to the type, severity and frequency of adverse events
experienced by patients (Figure 1). These differences in the
tolerability profiles of bevacizumab and sunitinib most likely
reflect their different mechanisms of action.
The most frequently reported grade 3– 4 adverse events in phase
III trials of bevacizumab plus IFN include fatigue and asthaenia,
hypertension, anorexia, bleeding, pyrexia and proteinuria; the
majority of these are mild to moderate and manageable, and only a
low incidence of grade 3–4 events is observed (Escudier et al,
2007; Rini et al, 2008). A retrospective subgroup analysis of the
AVOREN trial has shown that the tolerability of the regimen is
improved when lower doses of IFN are used in combination with
bevacizumab (Melichar et al, 2008): IFN dose reduction led to a
substantial decrease in the incidence of grade 3–4 adverse events 6
weeks after dose reduction compared with 6 weeks before dose
reduction (18 vs 44%), while efficacy was maintained.
The most frequently reported grade 3– 4 adverse events reported
with sunitinib as first-line treatment of metastatic RCC include
diarrhoea, vomiting, hypertension, hand-foot syndrome,
leucopaenia, neutropaenia, thrombocytopaenia and mucositosis
(Motzer et al, 2007; Negrier et al, 2008). The majority of adverse
events associated with sunitinib are managed by sunitinib dose
reduction or withdrawal (Sutent SmPC).
The development of severe adverse events is likely to require
additional treatment and/or hospitalisation. Adverse event
management costs, particularly hospitalisation, create an
additional demand on health-care resources. Thus, when making
a treatment choice for first-line RCC, the costs of managing
adverse events are an important consideration from the perspec-
tive of health-care providers and physicians. Currently, there are
few published data relating to management costs of adverse events
in patients with metastatic RCC. This paper presents the results of
a cost analysis to assess the estimated costs of managing adverse
events associated with bevacizumab plus IFN compared with those
associated with sunitinib for first-line treatment of RCC in the
United Kingdom, Germany, France and Italy.
MATERIALS AND METHODS
An Excel-based linear decision analytical model was developed to
calculate and compare the costs of management of all grades of
adverse events according to standard clinical practice for
bevacizumab plus IFN and sunitinib used as first-line treatment
of metastatic RCC. The model was populated using the total
incidence of grade 1– 4 adverse events reported in phase III trials
in this disease setting (Escudier et al, 2007; Motzer et al, 2007), and
with cost data associated with the management of adverse events
from the perspective of health-care providers in the United
Kingdom, Germany, France and Italy.
Cost data for the United Kingdom were obtained from a review
of the published literature in the MEDLINE database using the
adverse event description ‘type of adverse event’ and ‘cost’ and
‘UK’ and ‘RCC’. If this search strategy was unsuccessful, alternative
search strategies were ‘type of adverse event’ and ‘cost’ and ‘UK’
and ‘oncology’ or ‘type of adverse event’ and ‘cost’ and ‘UK’. The
same search terms were also used to obtain cost information from
the UK National Institute for Health and Clinical Excellence
(NICE). The primary perspective of this analysis was the same as
that of the UK National Health Service.
Cost data for Germany were calculated from the diagnosis-
related group (DRG) funding system catalogue (2008) and the
from Einheitlicher Bewertungsmabstab (EBM) catalogue 2008
(Diagnosis Related Groups in Germany 2008; G-DRG system
2008; Einheitlicher Bewertungsmabstab fu¨r a¨rztliche Leistungen,
Kassena¨rztliche Bundesvereinigung Berlin, 2008). Cost calculations
in the DRG system are all inclusive, reflecting the costs of
medicines, staff and maintenance, and provide an indication of the
total cost for treating adverse events assuming that there is no
severe underlying disease or complication. The EBM catalogue
assigns points and costs per point for physician activities
associated with costs of ambulatory treatment, but does not
include medication costs. In this study, EBM points were assigned
a value of h0.05; thus, 900 physician points corresponded to a cost
of h4.50. To take into account the 2009 changes in the German
EBM system, a point value of 3.5 cents was also applied.
In France, the cost of drugs was obtained from the Banque
Claude Bernard database (Banque Claude Bernard, Group
Cegedim, Boulogne Billancourt, France, 2007) and from the
Pharmacie centrale des Hopitaux de Paris (APHP) (Pharmacie
centrale des Hoˆpitaux de Paris, France, January, 2007). Costs for
laboratory tests and examinations were derived from official tariff
lists (Classification Commune des Actes Me´dicaux, CCAM V10,
2007; Table Nationale de codage de Biologie – Version 26
December, 2007). Hospitalisation costs (mean cost per stay) were
estimated using the French DRG hospital database and the Etude
Nationale de Couts (ENC) 2006 (Base de donne´es PMSI, 2006;
Etude Nationale de Couˆts, 2006).
The assessment for Italy used information on the cost of treating
adverse events from the report of a Delphi panel of experts
from five clinical practices (Capri et al, 2007), from the Italian
national DRG tariff (Conferenza delle Regioni e Province
Autonome) and data from studies by Nuijten et al (2002) and
Jansen et al (1997).
The base-case analysis conducted using the decision analytical
model included all grades of adverse events, using as a threshold
the cumulative total of events responsible for X80% of total
management costs. An additional scenario analysis was also
conducted based only on the costs of managing grade 3 –4 adverse
events. As modelling studies are associated with uncertainty
associated with input parameters, the robustness of the model was
tested using sensitivity analyses based on varying hospitalisation
costs within plus or minus 10% and by excluding the two most
costly adverse events for bevacizumab plus IFN and with sunitinib.
In Germany, medication costs are not included in the EBM cost
estimates. Therefore, in Germany only, additional sensitivity
analyses were conducted: first, 5% was added to the ambulatory
medication costs to capture the costs of medications used to
manage adverse events, and second, the effect of assigning a cost of
h0.03 or h0.06 per EBM physician point was investigated.
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Figure 1 Frequency and severity of principal adverse events in patients
with metastatic RCC treated with bevacizumab plus IFN or with sunitinib
(Escudier et al, 2007; Motzer et al, 2007; Negrier et al, 2008).
IFN¼ interferon-a2a; NR¼ not reported; RCC¼ renal call carcinoma.
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RESULTS
United Kingdom, Germany and France
The average cost per patient of managing all-grade and grade 3– 4
adverse events varied across the countries assessed (Table 1,
Figure 2). The linear decision analytical model demonstrated that
for all-grade and for grade 3 –4 adverse events, management costs
per patient were higher for sunitinib than for bevacizumab plus
IFN in the United Kingdom, Germany and France (Mickisch et al,
2008). All-grade adverse event management costs per patient in the
United Kingdom, Germany and France, respectively, were h1309,
h1477 and h1957 for bevacizumab plus IFN and h2350, h2071 and
h5127 for sunitinib. These differences represent potential cost
savings of h1041 (44%), h594 (29%) and h3170 (62%) per patient
in the United Kingdom, Germany and France, respectively, for
patients with metastatic RCC treated with bevacizumab plus IFN
compared with sunitinib.
A similar trend of higher management costs per patient with
sunitinib compared with bevacizumab plus IFN was observed for
grade 3 –4 adverse events (Figure 2). In the United Kingdom,
Germany and France, respectively, the management costs per
patient for grade 3 –4 adverse events were h804, h1367 and h1618
for bevacizumab plus IFN and h1475, h1785 and h2590 for
sunitinib. These differences represent the opportunity for cost
savings of h671 (45%), h418 (23%) and h972 (38%) per patient in
the United Kingdom, Germany and France, respectively, for
patients with metastatic RCC treated with bevacizumab plus IFN
compared with sunitinib.
The main drivers of adverse event management costs for
sunitinib and bevacizumab plus IFN were generally consistent
across the countries examined (Figure 3). Neutropaenia, lympho-
paenia, thrombocytopaenia, fatigue/asthaenia and anaemia were
the main drivers of management costs associated with sunitinib. In
contrast, proteinuria and fatigue/asthaenia were the main drivers
of management costs associated with bevacizumab plus IFN,
although bleeding, gastrointestinal (GI) perforation, anaemia and
neutropaenia were shown to be associated with high costs in
individual countries.
Sensitivity analyses based on a 10% difference in hospitalisation
costs and excluding the costs of treating the principal adverse
events associated with treatment were consistent with the overall
analyses and demonstrated that bevacizumab plus IFN remained
the least expensive treatment with respect to costs for managing
adverse events compared with sunitinib (Table 2). Additional
sensitivity analyses conducted in Germany showed that, even after
taking into account medication costs, physician costs and a point
value of 3.5 cents, bevacizumab plus IFN remained the least
expensive treatment with respect to costs for managing adverse
events compared with sunitinib. These sensitivity analysis findings
demonstrate that the analytical model was robust.
Italy
The results of the original analysis for the United Kingdom,
Germany and France indicated that the vast majority of manage-
ment costs for adverse events was associated with the development
of grade 3 –4 events. On this basis, only grade 3– 4 adverse events
were assessed for management costs in Italy (Procopio et al, 2008).
The average cost per patient of managing grade 3–4 adverse
events for sunitinib (h891) was higher than that for bevacizumab
plus IFN (h402); this difference represents an average cost saving of
h489 (55%) per patient (Figure 2). Consistent with the results in the
United Kingdom, Germany and France, sunitinib and bevacizumab
plus IFN had different main drivers of adverse event management
costs. Lymphopaenia, hypertension, thrombocytopaenia, diarrhoea
and leucopaenia were the main drivers for sunitinib treatment. In
contrast, venous thrombosis, fatigue/asthaenia, GI perforation and
hypertension were the main drivers of adverse event management
costs for bevacizumab.
Sensitivity analyses were consistent with the main results and
confirmed the cost savings of bevacizumab plus IFN in Italy. A
10% difference in hospitalisation costs and excluding the costs of
treating the principal adverse events associated with sunitinib and
bevacizumab plus IFN showed cost savings that were consistent
with those of other countries (Table 2).
DISCUSSION
The treatment of metastatic RCC has been transformed by the
recent introduction of molecularly targeted agents. Sunitinib and
bevacizumab, in combination with IFN, are approved for first-line
treatment of patients with metastatic RCC and recent clinical
studies demonstrate that they provide comparable levels of efficacy
(Escudier et al, 2007, 2009; Motzer et al, 2007; Coppin et al, 2008).
In an era in which there is a choice of effective therapy, a wide
range of factors should be considered when selecting treatment,
including overall tolerability profiles, ease of managing adverse
events and costs associated with adverse event management.
Sunitinib and bevacizumab plus IFN have tolerability profiles
that show important differences and are defined to varying
degrees. Common adverse events associated with bevacizumab
include hypertension, proteinuria and bleeding, whereas neutro-
paenia, leucopaenia, anaemia and hypertension are commonly
associated with sunitinib. These differences and the relative
definition of the drugs’ tolerability profiles are presumably related
to the mechanism of action of each of the agents. The common
adverse events associated with bevacizumab seem to be related
directly to its precise inhibition of VEGF signalling, with a defined
mechanism of action described for most. In contrast, sunitinib is a
multitargeted kinase inhibitor that has been shown to have activity
against a range of cell signalling pathways, as well as against VEGF,
and is therefore associated with both VEGF-specific and non-
VEGF-specific toxicity. However, the pathophysiology of many
sunitinib-associated adverse events, including rash, stomatitis,
cardiac effects and ‘chemotherapy-like’ events such as neutro-
paenia, anaemia and hand-foot syndrome, remains to be fully
elucidated.
This study used safety data from the two pivotal studies of
bevacizumab plus IFN and sunitinib, which also provided
independently confirmed PFS data showing that the two regimens
have comparable efficacy (Escudier et al, 2007, 2009; Motzer et al,
2007). In contrast, two recent indirect comparison meta-analyses
suggested that suntinib provides a superior PFS benefit
(Mills et al, 2009; Thompson Coon et al, 2009). Unlike these
meta-analyses, this study excluded data from CALGB 90206
because this trial was open label, did not report independently
confirmed data, used North American centres that have limited
experience of IFN and patients seemed to have a comparatively
poorer prognosis.
In this study, the costs of managing adverse events associated
with these therapies in the United Kingdom, Germany, France and
Italy were considerably higher for sunitinib than for bevacizumab
plus IFN. Modification of basic clinical and economic assumptions
(hospitalisation costs and the main cost-driving adverse events)
showed that the model remained stable over the entire range of
plausible values for a given parameter, and was therefore robust.
The main cost drivers for sunitinib were lymphopaenia, neutro-
paenia, thrombocytopaenia, leucopaenia and fatigue/asthaenia.
In contrast, the main cost drivers for the management of adverse
events associated with bevacizumab plus IFN were fatigue/
asthaenia, proteinuria, bleeding, anaemia and GI perforation.
The majority of the increased cost associated with sunitinib
was related to the management of haematological toxicities,
which accounted for little or none of the cost of managing
Bevacizumabþ IFN and sunitinib AE management costs in mRCC
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adverse events associated with bevacizumab plus IFN;
chemotherapy-related haematological adverse events are asso-
ciated with an economic burden due to costly hospitalisation/
treatment costs and negatively affect patient quality of life
(Elliott, 1996; Liou et al, 2007). This study also suggests that
sunitinib involves higher costs for the management of adverse
events that patients perceive as troublesome and affect their
everyday activities and well-being. For example, hand-foot
syndrome with sunitinib often manifests 3– 4 weeks after
treatment initiation (Hutson et al, 2008); it occurs predominantly
on pressure points on the hands and feet, making walking and
manual and sporting activities difficult. In addition, GI disorders
(e.g., diarrhoea and mucosal inflammation) are common with
sunitinib and can often be uncomfortable and embarrassing for
the patient, interrupting daily activities (e.g., work), as well as
interfering with nutrition in patients who may already be
compromised in this regard.
The management strategies available for dealing with adverse
events due to sunitinib and bevacizumab plus IFN may also be
relevant when choosing first-line treatment for RCC. Reducing
the dose of IFN used in combination with bevacizumab
substantially improves the tolerability and management of
IFN-related adverse events, enabling patients to remain on therapy
while maintaining efficacy (Melichar et al, 2008). These promising
data derived from a retrospective analysis of AVOREN need
to be confirmed, most likely from the ongoing prospective phase II
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Figure 2 Total average cost per patient of managing grade 3–4 adverse
events associated with bevacizumab plus IFN or with sunitinib in patients
with metastatic RCC. IFN¼ interferon-a2a; RCC¼ renal call carcinoma.
aMotzer et al, 2007; bNegrier et al, 2008; cEscudier et al, 2007.
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Figure 3 Cost distribution for management of adverse events with
sunitinib and bevacizumab plus IFN in the United Kindgdom, Germany,
France and Italy. aOn the basis of costs of managing grade 3–4 costs only;
badverse events with proportional cost o5% are grouped.
IFN¼ interferon-a2a; GI¼ gastrointestinal.
Table 2 Sensitivity analyses for the linear decision analytical model in the
United Kingdom, Germany, France and Italy
Sunitinib
costs
Bevacizumab
+ IFN
costs
Cost
savings
(%)
United Kingdom
Hospitalisation cost
Reduction 10% h2202 h1230 h972 (44)
Increase 10% h2497 h1391 h1106 (44)
Exclude main sunitinib adverse event
Lymphopaenia h2081 h1309 h772 (37)
Thrombocytopaenia h2040 h1239 h801 (39)
Both adverse events h1771 h1239 h532 (30)
Exclude main bevacizumab + IFN adverse event
Proteinuria h2305 h1023 h1282 (56)
Fatigue and asthaenia h2097 h1067 h1030 (49)
Both adverse events h2097 h780 h1317 (63)
Germany
5% increase ambulatory treatment h2085 h1482 h603 (29)
Value of points
Three points h2030 h1461 h569 (28)
Six points h2275 h1555 h720 (32)
Hospitalisation cost
Reduction 10% h1893 h1340 h553 (29)
Increase 10% h2250 h1613 h637 (28)
Exclude main sunitinib adverse event
Neutropaenia h1749 h1380 h369 (21)
Lymphopaenia h1756 h1477 h2279 (16)
Both adverse events h1434 h1380 h54 (4)
Exclude main bevacizumab + IFN adverse event
Fatigue and asthaenia h1848 h1054 h794 (43)
GI perforation h2071 h1358 h713 (34)
Both adverse events h1848 h935 h913 (49)
France
Hospitalisation cost
Reduction 10% h4867 h1795 h3073 (63)
Increase 10% h5386 h2118 h3267 (61)
Exclude main sunitinib adverse event
Anaemia h3926 h1730 h2196 (56)
Neutropaenia h4296 h1764 h2531 (59)
Both adverse events h3096 h1538 h1558 (50)
Exclude main bevacizumab + IFN adverse event
Fatigue/asthaenia h4896 h1521 h3375 (69)
Anaemia h3926 h1730 h2196 (56)
Both adverse events h3696 h1294 h2402 (65)
Italya
Hospitalisation cost
Reduction 10% h802 h362 h441 (55)
Increase 10% h981 h442 h538 (55)
Exclude main sunitinib adverse event
Lymphopaenia h675 h402 h273 (40)
Hypertension h750 h349 h401 (54)
Both adverse events h533 h349 h184 (35)
Exclude main bevacizumab + IFN adverse event
Venous thrombosis h891 h330 h561 (63)
Fatigue/asthaenia h858 h334 h524 (61)
Both adverse events h858 h263 h595 (69)
Abbreviations: GI¼ gastrointestinal; IFN¼ interferon-a2a. aOn the basis of costs of
managing grade 3–4 costs only.
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trial of bevacizumab plus 3 MIU IFN (BEVLiN). The ability to
improve tolerability by using lower doses of IFN in combination
with bevacizumab provides even greater cost savings compared
with sunitinib in the first-line treatment of metastatic RCC
(Mickisch et al, 2009). Sunitinib-related adverse events are
frequently managed by a dose reduction from 50 mg oral daily to
37.5 or 25 mg (Sutent SmPC), suggesting that lower doses of
sunitinib are better tolerated than the recommended dose, which
would presumably also reduce adverse event management costs.
However, recent evidence shows that PFS and ORR with sunitinib
correlate with drug exposure (Mendel et al, 2003; Houk et al,
2007), suggesting that dose reduction below a certain threshold
may reduce efficacy and thereby potentially affect patient
outcomes.
This study considered the cost of adverse event management
for bevacizumab plus IFN and sunitinib in the United
Kingdom, Germany, France and Italy. The average adverse event
management costs varied across these countries but showed
an overall trend of consistently lower costs for bevacizumab plus
IFN versus sunitinib. Management costs varied between the
countries, but country-specific cost calculations/tariff lists provide
a probable explanation. In addition, direct costs from a
prospective study may be needed to confirm the cost savings
observed in this study. The linear decision analytical model used in
this study used health-care costs according to standard clinical
practice from a variety of sources and relied on adverse event data
from individual clinical trials that may not be fully comparable or
reflective of adverse events in daily clinical practice. In addition,
the linear decision analytical model did not permit a statistical
analysis of the cost differences between sunitinib and bevacizumab
plus IFN nor did it permit an analysis of the effect of adverse
events on treatment efficacy; additional studies may be needed
to confirm these data. The study also highlights that there is
no standardisation of treatment methods or costs across
different countries, meaning that the potential effect of adverse
event management costs should be assessed on an individual
country basis. The poorly defined pathophysiology and manage-
ment strategies of many sunitinib-associated adverse events
may not have been captured by this analysis, that is, the potential
of having to try different management approaches to identify the
most effective may represent increased ‘hidden’ costs. Moreover,
the analysis used costs for the management of haematological
adverse events and hand-foot syndrome based on historical
chemotherapy-associated costs. This could have underestimated
the costs of managing sunitinib-associated adverse events.
However, the utilisation of chemotherapy-associated costs will
remain the standard approach until specific data for targeted
therapies are available. Finally, this study did not consider drug
administration costs or initial drug acquisition costs because
country-specific initiatives may result in significant cost differ-
ences, making standardisation across countries difficult.
In conclusion, this study demonstrated that the different
tolerability profiles of bevacizumab plus IFN and of sunitinib result
in markedly lower adverse event management costs for bevacizu-
mab plus IFN. As these regimens have comparable efficacy in the
first-line treatment of metastatic RCC, the predicted cost savings in
relation to the management of bevacizumab plus IFN could provide
benefits to physicians and payers and may be an important
consideration when making therapeutic choices. These findings
raise important points and potential resource benefits in the current
cost-conscious oncology environment, in which there is a demand
for novel agents that provide the greatest benefit.
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